HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adair, J. C. Articles by Morgan, N. Search for Related Content PubMed PubMed Citation Articles by Adair, J. C. Articles by Morgan, N. Related Collections All Clinical trials Clinical trials Randomized controlled (CONSORT agreement) Alzheimer's disease

Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease

From the Neurology Service, Albuquerque Veterans Affairs Medical Center and Department of Neurology (Dr. Adair), University of New Mexico; Geriatric Service (Dr. Knoefel), Albuquerque Veterans Affairs Medical Center and Department of Internal Medicine, University of New Mexico; and Veterans Affairs Cooperative Studies Pharmacy (N. Morgan), Albuquerque, NM.

Address correspondence and reprint requests to Dr. John Adair, Department of Neurology, University of New Mexico, School of Medicine, 915 Camino de Salud NE, Albuquerque, NM 87131-5281.

The antioxidant N-acetylcysteine (NAC) or placebo was administered in a double-blind fashion to patients who met National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria for probable AD. Testing for efficacy occurred after 3 and 6 months of treatment. Comparison of interval change favored NAC treatment on nearly every outcome measure, although significant differences were obtained only for a subset of cognitive tasks.

This article has been cited by other articles:

				A. Chan, J. Paskavitz, R. Remington, S. Rasmussen, and T. B. Shea Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension American Journal of Alzheimer's Disease and Other Dementias, January 1, 2009; 23(6): 571 - 585. [Abstract] [PDF]

				N. Nicolakakis, T. Aboulkassim, B. Ongali, C. Lecrux, P. Fernandes, P. Rosa-Neto, X.-K. Tong, and E. Hamel Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor {gamma} Agonist J. Neurosci., September 10, 2008; 28(37): 9287 - 9296. [Abstract] [Full Text] [PDF]

				P. K. Vayalil, M. Olman, J. E. Murphy-Ullrich, E. M. Postlethwait, and R.-M. Liu Glutathione restores collagen degradation in TGF-{beta}-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen Am J Physiol Lung Cell Mol Physiol, December 1, 2005; 289(6): L937 - L945. [Abstract] [Full Text] [PDF]

				B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence Epidemiol. Rev., December 1, 2002; 24(2): 248 - 268. [Full Text] [PDF]

				M. P. Mattson, S. L. Chan, and W. Duan Modification of Brain Aging and Neurodegenerative Disorders by Genes, Diet, and Behavior Physiol Rev, July 1, 2002; 82(3): 637 - 672. [Abstract] [Full Text] [PDF]